PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Pathology, Dalhousie University, Halifax, NS, Canada.\', \'Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada.\', \'Department of Biology, Dalhousie University, Halifax, NS, Canada.\', \'Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.\', \'Equipe 11 Labellisée Par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, INSERM U1138, Université de Paris, Sorbonne Université, Paris, France.\', \'Gustave Roussy Cancer Campus, Villejuif, France.\', \'Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.\', \'Institut Universitaire de France, Paris, France.\', \'Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.\', \'Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China.\', \'Department of Women\'s and Children\'s Health, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/2162402X.2020.1794424
?:doi
?:hasPublicationType
?:journal
  • Oncoimmunology
is ?:pmid of
?:pmid
?:pmid
  • 32923158
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.77
?:rankingScore_hIndex
  • 49
?:title
  • Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32923158>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32923158>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all